Hainan Sihuan Cardiovascular and Cerebrovascular Drug Research Institute

Hainan Sihuan Cardiovascular and Cerebrovascular Drug Research Institute is the primary research and development arm of Sihuan Pharmaceutical Holdings Group, focusing on the discovery and development of treatments for cardiovascular and cerebrovascular diseases. Based in Haikou, Hainan, the institute manages a robust portfolio of small molecule drugs and generic improvements aimed at addressing high-prevalence conditions such as stroke, hypertension, and myocardial infarction. It plays a critical role in Sihuan's strategy to maintain its market-leading position in the Chinese cardio-cerebrovascular (CCV) prescription drug market. The institute's work spans from early-stage drug discovery to clinical trial management and regulatory submission within the Hainan Free Trade Port. Its portfolio includes several blockbuster products in the Chinese market, such as Cinepazide Maleate and Olmestartan Medoxomil.